These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Studies on the cytotoxicity of cytosine arabinoside. Haanen C; Muus P; Raymakers R; Drenthe-Schonk A; Salden M; Wessels J Semin Oncol; 1985 Jun; 12(2 Suppl 3):120-9. PubMed ID: 3892698 [No Abstract] [Full Text] [Related]
23. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens. Zeremski V; Savić A Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049 [TBL] [Abstract][Full Text] [Related]
24. Prediction of the response of patients with acute nonlymphocytic leukemia to cytosine arabinoside (NSC-63878) therapy. Burns CP; Armentrout SA; Stjernholm RL Cancer Chemother Rep; 1972 Aug; 56(4):527-34. PubMed ID: 4507687 [No Abstract] [Full Text] [Related]
25. Randomized clinical trial of cystosine arabinoside and 6-thioguanine in remission induction and consolidation of adult nonlymphocytic acute leukemia. Lewis JP; Linman JW; Marshall GJ; Pajak TF; Bateman JR Cancer; 1977 Apr; 39(4):1387-96. PubMed ID: 322835 [TBL] [Abstract][Full Text] [Related]
26. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide. Estlin EJ; Yule SM; Lowis SP Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927 [TBL] [Abstract][Full Text] [Related]
27. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Winter JN; Variakojis D; Gaynor ER; Larson RA; Miller KB Cancer; 1985 Aug; 56(3):443-9. PubMed ID: 3859362 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446 [TBL] [Abstract][Full Text] [Related]
29. [Value of high-dose cytosine-arabinoside in the treatment of resistant acute leukemia]. Witz F; Olive D; Lederlin P; Bordigoni P; Troussard X; Grosbois B; Schaison G; Cornu G Presse Med; 1987 Feb; 16(4):159-62. PubMed ID: 2950446 [TBL] [Abstract][Full Text] [Related]
30. Recognition of drug resistance during remission induction therapy for acute non-lymphocytic leukemia: utility of day 6 bone marrow biopsy. Preisler H; Barcos M; Reese P; Priore RL; Pothier L Leuk Res; 1983; 7(1):67-75. PubMed ID: 6572773 [TBL] [Abstract][Full Text] [Related]
31. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia. Preisler HD; Rustum Y; Priore RL Eur J Cancer Clin Oncol; 1985 Jan; 21(1):23-30. PubMed ID: 4038655 [TBL] [Abstract][Full Text] [Related]
32. [The effect of cytosine arabinoside on cell kinetics in adult acute leukemia and its correlation to the therapeutic response]. Furusawa S; Adachi Y; Nomura T; Komiya M Rinsho Ketsueki; 1972 Dec; 13(6):943-50. PubMed ID: 4675065 [No Abstract] [Full Text] [Related]
33. Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia. Wiernik PH; Schimpff SC; Schiffer CA; Lichtenfeld JL; Aisner J; O'Connell MJ; Fortner C Cancer Treat Rep; 1976 Jan; 60(1):41-53. PubMed ID: 1069608 [TBL] [Abstract][Full Text] [Related]
34. Treatment of erythroleukemia with anthracycline antibiotics and cytosine arabinoside. Tamura K; Preisler HD Cancer; 1983 May; 51(10):1795-9. PubMed ID: 6572541 [TBL] [Abstract][Full Text] [Related]
35. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukaemia. Jensen MK; Ahlbom G Scand J Haematol; 1985 Mar; 34(3):261-3. PubMed ID: 3992192 [TBL] [Abstract][Full Text] [Related]
36. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update. Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687 [TBL] [Abstract][Full Text] [Related]
37. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study. Larson RA; Day RS; Azarnia N; Bennett JM; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A Br J Haematol; 1992 Oct; 82(2):337-46. PubMed ID: 1419816 [TBL] [Abstract][Full Text] [Related]
38. Sensitivity of normal and acute myelogenous leukaemia marrow cells to inhibition by cytosine arabinoside. Potter CG; Bunch C Br J Cancer; 1980 Jun; 41(6):985-8. PubMed ID: 6932908 [No Abstract] [Full Text] [Related]